Virtual Library

Start Your Search

Veysel Gökçek



Author of

  • +

    P1.09 - Pathology (Not CME Accredited Session) (ID 941)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.09-06 - The Incidence of PD-L1 in NSCLC and its Correlation with Driver Mutations in Turkish Patients; A Single Center Experience. (ID 12506)

      16:45 - 18:00  |  Author(s): Veysel Gökçek

      • Abstract
      • Slides

      Background

      PD-L1 testing have become the new standard of care for patient diagnosis in advance Non-Small Cell Lung Carcinoma (NSCLC). NSCLC also is characterized by driver mutations in epidermal growth factor receptor (EGFR), alterations anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1). This study aimed to evaluate and to compare with immunotherapy related biomarker PD-L1 and driver mutations biomarkers (EGFR, ALK, and ROS1) in Turkish patients with NSCLC retrospectively. PD-L1 positivity also was examined whether related to some clinico-pathological parameters in NSCLC patients.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A retrospective cohort composed of 650 consecutive patients diagnosis with NSCLC were tested for PD-L1 between November of 2016 and February of 2018. PD-L1 immunostaining was performed using and 22c3 (DAKO platform) or SP263 (Ventana platform). Pathology report were reviewed to collect patient demographic data, smoking status, tumor sup-types, and specimen types. For EGFR mutational analysis were examined using a real time assay (The cobas v2 ® EGFR Mutation Test). ALK and ROS1 translocations were evaluated by IHC + FISH method. For statistical analysis Pearson chi -square test was used.

      4c3880bb027f159e801041b1021e88e8 Result

      TABLE I

      Parameter

      PD-L1 status

      Statistic

      total

      <1%

      1-49%

      ≥50%

      P-value (Pearson
      Chi-Square)

      Age

      ≤60

      282 (44.4%)

      80 (28.4%)

      110 (39.0%)

      92 (32.6%)

      0.070

      >60

      353 (55.6%)

      113 (32.0%)

      154 (43.6%)

      86 (24.4%)

      Gender

      female

      140 (22.0%)

      46 (32.9%)

      65 (46.4%)

      29 (20.7%)

      0.090

      male

      495 (78.0%)

      147 (29.7%)

      199 (40.2%)

      149 (30.0%)

      Smoking

      no

      77 (14.4%)

      27 (35.1%)

      37 (48.1%)

      13 (16.9%)

      0.072

      yes

      456 (85.6%)

      143 (31.4%)

      179 (39.3%)

      134 (29.4%)

      Pathology

      adenoca

      404 (63.8%)

      134 (33.2%)

      171 (42.3%)

      99 (24.5%)

      0.018

      non-adenoca

      229 (36.2%)

      59 (25.8%)

      91 (39.7%)

      79 (34.5%)

      EGFR status

      wild type

      429 (90.7%)

      120 (28.0%)

      179 (41.0%)

      130 (30.3%)

      0.002

      exon 19

      26 (5.5%)

      17 (65.4%)

      7 (26.9%)

      2 (7.7%)

      exon 21

      13 (2.7%)

      6 (46.2%)

      6 (46.2%)

      1 (7.7%)

      others

      5 (1.1%)

      2 (40.0%)

      1 (20.0%)

      2 (40.0%)

      ALK status

      negative

      414 (94.7%)

      116 (28.0%)

      177 (42.8%)

      121 (29.2%)

      0.890

      positive

      23 (5.3%)

      6 (26.1%)

      11 (47.8%)

      6 (26.1%)

      ROS1 status

      negative

      412 (97.6%)

      116 (28.2%)

      179 (43.4%)

      117 (28.4%)

      0.251

      positive

      10 (2.4%)

      1 (10.0%)

      4 (40.0%)

      5 (50.0%)

      Clinico-pathological characteristics of NSCLC patients (n=650) and their relationships with PD-L1 expression were presented on Table I.

      8eea62084ca7e541d918e823422bd82e Conclusion

      This is the first study to compare PD-L1 expression with clinico-pathological parameters in Turkish NSCLC patients (n=650).

      The majority of Turkish patients were smokers (85.6%). Although there was no statistical significance between PD-L1 positivity and smoking status, smoker patients showed more PD-L1 high tumor proportion score (H-TPS = ≥50%) than non-smoker patients; 29.4% to 16.9% respectively.

      The majority of patients were Adenocarcinoma patients (63.8%).

      PD-L1 positivity was higher in Non-adenocarcinoma patients than Adenocarcinomas (p=0.018).

      This study demonstrated that PD-L1 positivity in lung adenocarcinoma, was strongly associated with EGFR wild-type status (p=0.002) which was parallel to literature.

      There was no correlation between ALK and ROS1 translocation with PD-L1 status.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.